Construction company, ITD Cementation India has bagged orders worth Rs. 1,066 crore from Airport Authority of India, Vizhinjam Port, Mumbai Metro and Rail Vikas Nigam.

The NII for the quarter increased by 2 per cent yoy and 3.2 per cent qoq to Rs. 103.39 crore in Q2FY19 as against Rs. 126.3 crore in Q1FY19 and Rs. 127.85 crore in Q2FY18. The interest income for the company grew by 12.2 per cent yoy to Rs. 414.2 crore in Q2FY19 vs Rs. 369.24 crore in Q2FY18.

The company informed the exchanges that its manufacturing plant in Boisar, near Mumbai has received an order for closure of the plant from Maharashtra Pollution Control Board (MPCB).

Himachal Futuristic Communications (HFCL), telecom network turnkey implementation company announced that it has received an Advance Purchase Order worth approximately Rs. 366.36 crore from Bharat Sanchar Nigam (BSNL), New Delhi.

Overall volumes in futures & options currently stand at 1.04 crore contracts with a turnover of Rs. 8,71,268 crore.

Overall volumes in futures & options currently stand at 1.04 crore contracts with a turnover of Rs. 8,71,268 crore.

The opening on Tuesday and the path that the Nifty takes post opening would be crucial as the levels of 10,138-10,200 would be extremely vital to watch out in the event of any vulnerability. Stocks in news: HFCL, ITD Cementation India, Rural Electrification Corporation, Digjam, Syndicate Bank, BHEL and Orient Press.

The SGX Nifty is trading down by almost 86 points and that could have an impact on the Indian markets even as the Asian peers are deep in the red. The SGX Nifty indicates Nifty may open with deep cut of almost 0.88 per cent around the level of 10,162.50. Among Nifty 50 companies, Adani Ports, Bajaj Finserv, Bajaj Finance and HCL Technologies will report their earnings today.  

Mumbai based real estate firm, Oberoi Realty’s consolidated revenue for the second quarter of FY19 came in at Rs. 592.11 crore, registering 95.1 per cent yoy increase. 

Jubilant Life Sciences’ consolidated revenue for the quarter ended on September 2018 stood at Rs. 2,269 crore, up by 38 per cent YoY. This was led by stellar performance across all the segment, Pharmaceuticals division which account for 58 per cent of revenue recorded 55 per cent yoy growth.